Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Total Non-Current Liabilities readings, the most recent being $194.3 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 42.12% to $194.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $194.3 million, a 42.12% increase, with the full-year FY2025 number at $177.5 million, up 26.52% from a year prior.
  • Total Non-Current Liabilities hit $194.3 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $177.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $194.3 million in Q1 2026 to a low of $50.9 million in Q1 2023.
  • Median Total Non-Current Liabilities over the past 5 years was $85.9 million (2024), compared with a mean of $106.8 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 95.45% in 2022 and later dropped 21.05% in 2023.
  • Kiniksa Pharmaceuticals International's Total Non-Current Liabilities stood at $61.7 million in 2022, then soared by 38.81% to $85.6 million in 2023, then soared by 63.85% to $140.3 million in 2024, then increased by 26.52% to $177.5 million in 2025, then rose by 9.45% to $194.3 million in 2026.
  • The last three reported values for Total Non-Current Liabilities were $194.3 million (Q1 2026), $177.5 million (Q4 2025), and $162.4 million (Q3 2025) per Business Quant data.